Influence of significant weight loss on serum matrix metalloproteinase (MMP)-7 levels

European Cytokine Network

Volumn 21, Issue 1, 2010, Pages 65-70

  Ress, Claudia ^a   Tschoner, Alexander ^a   Ciardi, Christian ^a   Laimer, Markus W ^a   Engl, Julia W ^a   Sturm, Wolfgang ^a   Weiss, Helmut ^a   Tilg, Herbert ^a   Ebenbichler, Christoph F ^a   Patsch, Josef R ^a   Kaser, Susanne ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Adipose tissue; Matrix metalloproteinase; Obesity; Weight loss

Indexed keywords

GELATINASE A; GLUCOSE; LIPID; MATRILYSIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MORBID OBESITY; PROSPECTIVE STUDY; WEIGHT REDUCTION;

ADULT; BARIATRIC SURGERY; FEMALE; HEALTH; HUMANS; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; OBESITY; THINNESS; WEIGHT LOSS; YOUNG ADULT;

EID: 77149142914     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2009.0177     Document Type: Article

References (34)

1. Sternlicht MD and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463.
2. Nagase H, Visse R and Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562.
3. Lemaitre V, D'Armiento J. Matrix metalloproteinases in development and disease. Birth Defects Res C Embryo Today 2006; 78: 1.
4. Laimer M, Kaser S, Kranebitter M, et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes (Lond) 2005; 29: 498.
5. Ye ZX, Leu HB, Wu TC, Lin SJ and Chen JW. Baseline serum matrix metalloproteinase-9 level predicts long-term prognosis after coronary revascularizations in stable coronary artery disease. Clin Biochem 2008; 41: 292.
6. Chavey C, Mari B, Monthouel MN, et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 2003; 278: 11888.
7. Bourlier V, Zakaroff-Girard A, De Barros S, et al. Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation. J Pharmacol Exp Ther 2005; 312: 1272.
8. Maquoi E, Munaut C, Colige A, Collen D and Lijnen HR. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002; 51: 1093.
9. Derosa G, D'Angelo A, Scalise F, et al. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007; 22: 361.
10. Boden G, Song W, Pashko L, Kresge K. In vivo effects of insulin and free fatty acids on matrix metalloproteinases in rat aorta. Diabetes 2008; 57: 476.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412.
12. Engl J, Sturm W, Sandhofer A, et al. Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms. Eur J Clin Invest 2008; 38: 238.
13. Pontiroli AE, Pizzocri P, Giacomelli M, et al. Ultrasound measurement of visceral and subcutaneous fat in morbidly obese patients before and after laparoscopic adjustable gastric banding: comparison with computerized tomography and with anthropometric measurements. Obes Surg 2002; 12: 648.
14. Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity. Eur J Endocrinol 2008; 158: 135.
15. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683.
16. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753.
17. Lijnen HR, Van HB, Frederix L, Rio MC and Collen D. Adipocyte hypertrophy in stromelysin-3 deficient mice with nutritionally induced obesity. Thromb Haemost 2002; 87: 530.
18. Lijnen HR, Demeulemeester D, Van Hoef B, Collen D, Maquoi E. Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Thromb Haemost 2003; 89: 249.
19. Demeulemeester D, Collen D, Lijnen HR. Effect of matrix metalloproteinase inhibition on adipose tissue development. Biochem Biophys Res Commun 2005; 329: 105.
20. Glowinska-Olszewska B, Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007; 56: 799.
21. Derosa G, Ferrari I, D'Angelo A, et al. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008; 15: 219.
22. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881.
23. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 128: 837.
24. Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1281.
25. Alwayn IP, Andersson C, Lee S, et al. Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol 2006; 291: G1011.
26. Demeulemeester D, Scroyen I, Voros G, et al. Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development. Thromb Haemost 2006; 95: 1019.
27. Klein S, Mittendorfer B, Eagon JC, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006; 130: 1564.
28. Kralisch S, Bluher M, Tonjes A, et al. Tissue inhibitor of metalloproteinase-1 predicts adiposity in humans. Eur J Endocrinol 2007; 156: 257.
29. Fernandez CA, Moses MA. Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4. Biochem Biophys Res Commun 2006; 345: 523.
30. Van Hul M, Lijnen HR. A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost 2008; 6: 1198.
31. Unoki H, Bujo H, Jiang M, Kawamura T, Murakami K, Saito Y. Macrophages regulate tumor necrosis factor-alpha expression in adipocytes through the secretion of matrix metalloproteinase-3. Int J Obes (Lond) 2008; 32: 902.
32. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860.
33. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005; 102: 15575.
34. Traurig MT, Permana PA, Nair S, Kobes S, Bogardus C, Baier LJ. Differential expression of matrix metalloproteinase 3 (MMP3) in preadipocytes/stromal vascular cells from nonobese nondiabetic versus obese nondiabetic Pima Indians. Diabetes 2006; 55: 3160.